Video
New Episode of “One Expert – One Minute”
We are pleased to announce Episode 11 of our “One Expert – One Minute” series. This episode was recorded at the Falk Symposium “Gastrointestinal Inflammation and Neoplasia” in Warsaw.
In Episode 11, Prof. Ana Gutiérrez-Casbas (Alicante) discusses the importance of monitoring in inflammatory bowel diseases (IBD). She emphasizes the value of combining different monitoring tools, including intestinal ultrasound and fecal calprotectin, to optimize patient management both at diagnosis and throughout the long-term course of the disease.
Watch Episode 11 with Prof. Ana Gutiérrez-Casbas on “Monitoring in IBD” now:
In “One Expert – One Minute,” leading researchers share short, concise expert statements that deliver key insights and current perspectives on important topics in gastroenterology and hepatology — clear, focused, and to the point.
Stay tuned for more inspiring one-minute insights from international experts — more episodes will follow soon!
One Expert – One Minute
Episode 11
Prof. Ana Gutiérrez-Casbas, Alicante: Monitoring in IBD
Science Movie Warsaw
Long-term medical therapy or early surgical intervention?
In this lecture, three doctors, E. Tulewicz-Marti, F. Rieder and W. A. Bemelman, are discussing evolving perspectives in inflammatory bowel disease management and the multidisciplinary collaboration shaping its future.
Symposium 243, “Gastrointestinal Inflammation and Neoplasia,” held in Warsaw, Poland, in April 2026.
Gharahdaghi N et al, N Engl J Med. 2026;394(22):2212-2222
IL-10 autoantibodies in inflammatory bowel disease: Neutralizing IL-10 autoantibodies were present in a small subgroup (3,5%) of patients with IBD and were strongly associated with HLA-DRB1*01:03, the strongest genetic risk factor of ulcerative colitis.
Bando H et al, Nat Med. 2026;32(7):2473-2480
Post-adjuvant chemotherapy in circulating tumor DNA (ctDNA)-positive patients with resected colorectal cancer: post-adjuvant chemotherapy did not result in significant longer disease-free survival as compared to placebo in this prospective phase III trial (ALTAIR) in ctDNA-positive patients without radiological disease.
Verma M et al, JAMA Intern Med. 2026;186(6):677-686
Palliative care in end-stage liver disease – Hepatologist-led care achieves comparable outcomes: This cluster-randomized trial across 19 US centers included 935 patients with decompensated cirrhosis or hepatocellular carcinoma and compared 4 structured palliative care visits delivered by trained hepatologists with specialist palliative care. Quality of life improved at 3 months in both groups, with hepatologist-delivered care being noninferior to specialist palliative care; symptom burden and depression also improved similarly. The findings demonstrate that, with appropriate training, palliative care can be effectively integrated into hepatology practice.
Dongelmans E et al, J Hepatol. 2026;85(1):61-70
Stopping nucleos(t)ide analogues in chronic hepatitis B – Long-term outcomes from the RETRACT-B cohort: The international RETRACT-B cohort evaluated long-term outcomes after nucleos(t)ide analogue treatment cessation in patients with chronic hepatitis B. During long-term follow-up, a small proportion of patients achieved HBsAg loss, while virological and clinical relapses requiring retreatment remained frequent. These findings suggest that carefully monitored treatment cessation may be an option in selected patients with low HBsAg titers but requires close and long-term follow-up.
Leijonmarck W et al, Gastroenterology. 2026;171(3):481-488
Achalasia and esophageal cancer risk: Achalasia was strongly associated with esophageal squamous cell carcinoma in a nordic population-based study. The association with esophageal adenocarcinoma was less strong and largely explained by gastroesophageal reflux.
Forbes N et al, Gastroenterology. 2026;171(2):342-353
Cardiovascular outcomes following gastrointestinal bleeding: patients with pre-existing cardiovascular disease and major gastrointestinal bleeding in a large prospective multicenter study (INTERBLEED) had an increased risk to die which was determined by delayed resumption of antithrombotic therapies.
Walter T et al, Lancet. 2026;408(10551):234-247
Peptide receptor radionuclide ([177Lu]Lu-edotreotide) vs. everolimus for gastroenteropancreatic neuroendocrine tumours (GEP): [177Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival in a randomized phase III trial (COMPETE). Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early lines of therapy in patients with advanced, progressive GEP neuroendocrine tumors.
Events
Symposium
Symposium: Liver Crosstalk – Immunity, Metabolism, and Tumor Biology
January 28 – 29, 2027, Tübingen, Germany
Kino Museum Tübingen, Am Stadtgraben 2, 72070 Tübingen, Germany
Symposium 246
Metabolic Syndrome and Liver Disease
March 12 – 13, 2027, Valencia, Spain
Palacio de Congresos de Valencia, Avenida de las Cortes Valencianas 60, 46015 Valencia, Spain
Symposium 247
Experimental Hepatology Days
May 13 – 15, 2027, Freiburg, Germany
Konzerthaus Freiburg, Konrad-Adenauer Platz 1, 79098 Freiburg, Germany
Current Falk literature:
Inflammatory Bowel Diseases
Radiological Diagnostics
Author: M. Juchems
(51 pages)